Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more - The Niche
Sweet Spot: CRISPR Therapeutics, ViaCyte Dose First Patient with Cell Therapy for Type 1 Diabetes
A genome-wide CRISPR screen identifies regulators of beta cell function involved in type 2 diabetes risk | bioRxiv
CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination - eBioMedicine
The Most Innovative Ways to Use CRISPR | OpenMind
CRISPR/Cas9 system - a revolution in gene editing
CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review | PLOS ONE
Reversing diabetes with CRISPR and patient-derived stem cells | Fierce Biotech
CRISPR-based genome editing in primary human pancreatic islet cells | Nature Communications
ViaCyte | Regenerative Medicine Therapies for Diabetes
News: First CRISPR Therapy for Type 1 Diabetes Set to Enter Clinical Trial - CRISPR Medicine
Frontiers | Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement
CRISPR Therapeutics and ViaCyte Tackling Type 1 Diabetes - YouTube
Forscher heilen Diabetes bei Mäusen mit genkorrigierten menschlichen...
ViaCyte and CRISPR Introduce New Stem Cell Therapy for Type 1 Diabetes
Modeling Type 1 Diabetes In Vitro Using Human Pluripotent Stem Cells - ScienceDirect
Diabetology | Free Full-Text | Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes
Looking into the possibilities of cure of the type 2 diabetes mellitus by nanoparticle-based RNAi and CRISPR-Cas9 system: A review - ScienceDirect
CRISPR Therapeutics and ViaCyte, Inc. Announce First
Type-2 Diabetes and Gene Therapy: The Promise of CRISPR Gene Therapy in type-2 Diabetes Mellitus - Open Access Pub
CRISPR-Cas9 successfully reverses obesity in mice
ActoBio's Cheese-Producing Bacteria Could Reverse Type 1 Diabetes
Cells | Free Full-Text | Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet?
Stem Cells and the Search For a Type 1 Diabetes Cure
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis | NEJM
Type 1 diabetes risk genes mediate pancreatic beta cell survival in response to proinflammatory cytokines - ScienceDirect
CRISPR for Type 1 & 2 Diabetes Identification and Treatment | IDT
